M&T Bank
KYMR icon

M&T Bank’s Kymera Therapeutics KYMR Stock Holding History

M&T Bank’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
+1,826
New +$157K ﹤0.01% 1635

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

M&T Bank's KYMR Position: Q2 2026 in Review

M&T Bank opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 1,826 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #1635 among its holdings.

275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • M&T Bank held 1,826 shares of Kymera Therapeutics worth $209K as of Q2 2026.
  • Kymera Therapeutics was a new M&T Bank position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1635 holding.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.